NHS Logo

Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. (Record no. 75852)

MARC details
000 -LEADER
fixed length control field 07888cam a2200301 4500
001 - CONTROL NUMBER
control field NMDX6729
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 120401t2015 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 22132600
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Navani, N.
240 ## - UNIFORM TITLE
Uniform title <a href="The Lancet Respiratory Medicine">The Lancet Respiratory Medicine</a>
245 ## - TITLE STATEMENT
Title Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial.
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Date of publication, distribution, etc. 2015
500 ## - GENERAL NOTE
General note NMUH Staff Publications
500 ## - GENERAL NOTE
General note 3
520 ## - SUMMARY, ETC.
Summary, etc. &lt;h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif; line-height: 17.9998016357422px;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;span style="font-family: Arial;"&gt;BACKGROUND:&lt;/span&gt;&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em; font-family: arial, helvetica, clean, sans-serif; font-size: 13px; line-height: 17.9998016357422px;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;span style="font-family: Arial;"&gt;The&amp;nbsp;&lt;span class="highlight"&gt;diagnosis&lt;/span&gt;&amp;nbsp;and&amp;nbsp;&lt;span class="highlight"&gt;staging&lt;/span&gt;&amp;nbsp;of&amp;nbsp;&lt;span class="highlight"&gt;lung&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;cancer&lt;/span&gt;&amp;nbsp;is an important process that identifies treatment options and guides disease prognosis. We aimed to assess&amp;nbsp;&lt;span class="highlight"&gt;endobronchial&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;ultrasound-guided&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;transbronchial&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;needle&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;aspiration&lt;/span&gt;&amp;nbsp;as an initial investigation technique for patients with suspected&lt;span class="highlight"&gt;lung&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;cancer&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif; line-height: 17.9998016357422px;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;span style="font-family: Arial;"&gt;METHODS:&lt;/span&gt;&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em; font-family: arial, helvetica, clean, sans-serif; font-size: 13px; line-height: 17.9998016357422px;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;span style="font-family: Arial;"&gt;In this&amp;nbsp;&lt;span class="highlight"&gt;open-label&lt;/span&gt;, multicentre,&amp;nbsp;&lt;span class="highlight"&gt;pragmatic&lt;/span&gt;,&amp;nbsp;&lt;span class="highlight"&gt;randomised&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;controlled&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;trial&lt;/span&gt;, we recruited patients who had undergone a CT scan and had suspected stage I to IIIA&amp;nbsp;&lt;span class="highlight"&gt;lung&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;cancer&lt;/span&gt;, from six UK centres and randomly assigned them to either&amp;nbsp;&lt;span class="highlight"&gt;endobronchial&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;ultrasound-guided&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;transbronchial&lt;/span&gt;&lt;span class="highlight"&gt;needle&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;aspiration&lt;/span&gt;&amp;nbsp;(EBUS-TBNA) or&amp;nbsp;&lt;span class="highlight"&gt;conventional&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;diagnosis&lt;/span&gt;&amp;nbsp;and&amp;nbsp;&lt;span class="highlight"&gt;staging&lt;/span&gt;&amp;nbsp;(CDS), for further investigation and&amp;nbsp;&lt;span class="highlight"&gt;staging&lt;/span&gt;. If a target node could not be accessed by EBUS-TBNA, then endoscopic&amp;nbsp;&lt;span class="highlight"&gt;ultrasound-guided&lt;/span&gt;&amp;nbsp;fine&amp;nbsp;&lt;span class="highlight"&gt;needle&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;aspiration&lt;/span&gt;&amp;nbsp;(EUS-FNA) was allowed as an alternative procedure. Randomisation was stratified according to the presence of mediastinal lymph nodes measuring 1 cm or more in the short axis and by recruiting centre. We used a telephone randomisation method with permuted blocks of four generated by a computer. Because of the nature of the intervention, masking of participants and consenting investigators was not possible. The primary endpoint was the time-to-treatment decision after completion of the diagnostic and&amp;nbsp;&lt;span class="highlight"&gt;staging&lt;/span&gt;&amp;nbsp;investigations and analysis was by intention-to-diagnose. This&amp;nbsp;&lt;span class="highlight"&gt;trial&lt;/span&gt;&amp;nbsp;is registered with ClinicalTrials.gov, number&lt;a href="http://clinicaltrials.gov/show/NCT00652769" title="See in ClincalTrials.gov" style="border-bottom-width: 0px;"&gt;NCT00652769&lt;/a&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif; line-height: 17.9998016357422px;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;span style="font-family: Arial;"&gt;FINDINGS:&lt;/span&gt;&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em; font-family: arial, helvetica, clean, sans-serif; font-size: 13px; line-height: 17.9998016357422px;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;span style="font-family: Arial;"&gt;Between June 10, 2008, and July 4, 2011, we randomly allocated 133 patients to treatment: 66 to EBUS-TBNA and 67 to CDS (one later withdrew consent). Two patients from the EBUS-TBNA group underwent EUS-FNA. The median time to treatment decision was shorter with EBUS-TBNA (14 days; 95% CI 14-15) than with CDS (29 days; 23-35) resulting in a hazard ratio of 1·98, (1·39-2·82, p&amp;lt;0·0001). One patient in each group had a pneumothorax from a CT-guided biopsy sample; the patient from the CDS group needed intercostal drainage and was admitted to hospital.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif; line-height: 17.9998016357422px;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;span style="font-family: Arial;"&gt;INTERPRETATION:&lt;/span&gt;&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em; font-family: arial, helvetica, clean, sans-serif; font-size: 13px; line-height: 17.9998016357422px;"&gt;&lt;span style="font-family: Arial;"&gt;&lt;span style="font-size: 8pt;"&gt;&lt;span class="highlight"&gt;Transbronchial&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;needle&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;aspiration&lt;/span&gt;&amp;nbsp;guided by&amp;nbsp;&lt;span class="highlight"&gt;endobronchial&lt;/span&gt;&amp;nbsp;ultrasound should be considered as the initial investigation for patients with suspected&amp;nbsp;&lt;span class="highlight"&gt;lung&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;cancer&lt;/span&gt;, because it reduces the time to treatment decision&amp;nbsp;&lt;span class="highlight"&gt;compared&lt;/span&gt;&amp;nbsp;with&amp;nbsp;&lt;span class="highlight"&gt;conventional&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;diagnosis&lt;/span&gt;&amp;nbsp;and&amp;nbsp;&lt;span class="highlight"&gt;staging&lt;/span&gt;techniques.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Nankivell, M.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Lawrence, D.R.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Lock, S.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Makker, H.K.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Baldwin, D.R.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Stephens, R.J.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Parmar, M.K.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Spiro, S.G.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Morris, S.
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Janes, S.M.
710 ## - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element Lung-BOOST trial investigators
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://www.sciencedirect.com/science/article/pii/S2213260015000296">http://www.sciencedirect.com/science/article/pii/S2213260015000296</a>
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection code Home library Current library Shelving location Date acquired Total Checkouts Date last seen Price effective from Koha item type
        Staff publications for NMDX Ferriman information and Library Service (North Middlesex) Ferriman information and Library Service (North Middlesex) Online 07/06/2022   07/06/2022 07/06/2022 UNKNOWN
London Health Libraries Consortium Privacy notice and Membership terms and conditions